1142227-35-7

Basic information

• Product Name: 5-Bromo-2-fluoro-4-hydroxy-benzoic acid methyl ester
• Synonyms: 5-Bromo-2-fluoro-4-hydroxy-benzoic acid methyl ester;Methyl 5-bromo-2-fluoro-4-hydroxybenzoate
• CAS NO: 1142227-35-7
• Molecular Formula: C₈H₆BrFO₃
• Molecular Weight: 249.04
• Mol File: 1142227-35-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-Bromo-2-fluoro-4-hydroxy-benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-2-fluoro-4-hydroxy-benzoic acid methyl ester(1142227-35-7)
• EPA Substance Registry System: 5-Bromo-2-fluoro-4-hydroxy-benzoic acid methyl ester(1142227-35-7)

Safety Data

• Hazardous Substances Data: 1142227-35-7(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
5-Bromo-2-fluoro-4-hydroxy-benzoic acid methyl ester is used as a key intermediate in the synthesis of complex organic compounds with potential therapeutic applications. Its unique structural features make it a valuable building block for creating novel pharmaceuticals.
Used in Pharmaceutical Research:
In the field of pharmaceutical research, 5-Bromo-2-fluoro-4-hydroxy-benzoic acid methyl ester is employed as a precursor for the development of new drugs. Its potential anti-inflammatory, antioxidant, and antimicrobial properties are currently under investigation, with the aim of fully understanding its pharmacological potential and exploring its use in treating various diseases.
Used in Drug Development:
5-Bromo-2-fluoro-4-hydroxy-benzoic acid methyl ester is utilized in drug development as a starting material for the synthesis of innovative pharmaceuticals. Its versatility in organic synthesis allows for the creation of diverse compounds with potential therapeutic benefits, contributing to the advancement of medicinal chemistry.
Used in Organic Synthesis:
In the realm of organic synthesis, 5-Bromo-2-fluoro-4-hydroxy-benzoic acid methyl ester is used as a versatile reagent for the preparation of a wide range of organic compounds. Its unique functional groups enable various chemical reactions, facilitating the synthesis of complex molecules with potential applications in various industries.
Overall, 5-Bromo-2-fluoro-4-hydroxy-benzoic acid methyl ester is a valuable chemical compound with a broad spectrum of potential applications in the fields of medicinal chemistry, pharmaceutical research, drug development, and organic synthesis. Its unique structural properties and potential biological activities make it a promising candidate for the development of new therapeutic agents and the synthesis of complex organic compounds with diverse applications.

Upstream product

• 197507-22-5 methyl 2-fluoro-4-hydroxybenzoate 
• 65145-13-3 2-fluoro-4-hydroxybenzoic acid 
• 67-56-1 methanol 

Downstream Products

• 1142227-36-8 methyl 5-bromo-2-fluoro-4-(tetrahydro-2H-pyran-2-yloxy)benzoate 
• 949465-86-5 5-methyl 5-bromo-2-fluoro-4-methoxybenzoate 
• 1142227-40-4 methyl 5-(5,5-dimethylcyclopent-1-enyI)-2-fluoro-4-hydroxybenzoate 
• 1142227-38-0 methyl 5-(5,5-dimethylcyclopent-1-enyl)-2-fluoro-4-(tetrahydro-2H-pyran-2-yloxy)benzoate 
• 1142227-42-6 methyl 5-(5,5-dimethylcyclopent-1-enyl)-2-fluoro-4-(trifluoromethylsulfonyloxy)benzoate 
• 1142227-44-8 methyl 2-(5,5-dimethyl-1-cyclopenten-1-yl)-2',5-difluoro-5'-(methyloxy)-1,1'-biphenyl-4-carboxylate 

Relevant articles and documents

Seven-membered ring compound and application thereof in prevention and treatment of diabetes and metabolic syndrome

The invention discloses a seven-membered ring compound and application thereof in prevention and treatment of diabetes and metabolic syndrome. The structure of the seven-membered ring compound is as shown in a general formula I, and definitions of substituent groups are as shown in the specification and claims. The seven-membered ring compound of the invention has an extremely excellent effect ofpreventing or treating diabetes and metabolic syndrome.

N-SULFONYL BENZAMIDE DERIVATIVE WITH HETEROCYCLIC SUBSTITUENT, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF

The present invention discloses an N-sulfonyl benzamide derivative with a heterocyclic substituent, and a preparation method therefor and a pharmaceutical application thereof. More specifically, the invention discloses a compound represented by formula (II) or a pharmaceutically acceptable salt, stereoisomer, solvent compound, or prodrug thereof, and a preparation method therefor and an application thereof. Refer to the specification for definitions of each group in the formula.

BROMODOMAIN INHIBITOR

The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.

BROMODOMAIN INHIBITORS

The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.

SPIROCYCLIC GPR40 MODULATORS

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I'A or I'B, where the definitions of the variables are provided herein. The present invention also

CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.